{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:51:56Z","timestamp":1783691516377,"version":"3.55.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Previous studies on the association between cytomegalovirus (CMV) infection and cardiac allograft vasculopathy (CAV) were conducted on patients transplanted in the prevalganciclovir prophylaxis era. The aim of our study is to evaluate this relation in heart transplantation (HTx) recipients treated according to current prophylactic and immunosuppressive regimens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>This single-center retrospective study included all consecutive adult patients that underwent HTx between January 1, 2000, and May 31, 2018. Clinically relevant CMV infection was defined as either plasma CMV DNAemia \u2265 1000 IU\/mL with\/without clinical symptoms or &lt;1000 IU\/mL with symptoms. The primary endpoint was first manifestation of CAV diagnosed by coronary angiography. For statistical analysis, the cause-specific hazard regression model was applied, with clinically relevant CMV infection and any CMV infection as time-dependent variables.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>In total, 260 patients were included in the analysis. The median (interquartile range) follow-up was 7.88 (4.21\u201312.04) years. During the follow-up, clinically relevant CMV infection was diagnosed in 96 (37%) patients and CAV in 149 (57%) patients. In the multivariate regression analysis, independent predictors of CAV were: number of rejection episodes (cause-specific hazard ratio [95% confidence interval]: 1.18 [1.04-1.34], <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.01), hypertension (1.61 [1.11-2.34], <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.01), treatment with mycophenolate mofetil (0.68 [0.47-0.97], <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03). No significant association was observed between CMV infection and CAV, except for patients who experienced a breakthrough CMV infection (n = 24) during prophylaxis (1.94 [1.11-3.40], <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>In the era of contemporary immunosuppression and valganciclovir prophylaxis, a significant effect of CMV infection on the risk of CAV was seen only among HTx recipients with CMV breakthrough infection.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003015","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T15:08:44Z","timestamp":1571843324000},"page":"1508-1518","source":"Crossref","is-referenced-by-count":27,"title":["The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis"],"prefix":"10.1097","volume":"104","author":[{"given":"Dominika","family":"Klimczak-Tomaniak","sequence":"first","affiliation":[{"name":"Department of Cardiology, Thorax Center, Erasmus MC, University Medical Center Rotterdam, the Netherlands."},{"name":"Department of Immunology, Transplantation and Internal Medicine & Division of Heart Failure and Cardiac Rehabilitation, Medical University of Warsaw, Warsaw, Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Roest","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thorax Center, Erasmus MC, University Medical Center Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper J.","family":"Brugts","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thorax Center, Erasmus MC, University Medical Center Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadir","family":"Caliskan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thorax Center, Erasmus MC, University Medical Center Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Kardys","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thorax Center, Erasmus MC, University Medical Center Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Zijlstra","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thorax Center, Erasmus MC, University Medical Center Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina A.","family":"Constantinescu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thorax Center, Erasmus MC, University Medical Center Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanda J.C.","family":"Voermans","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC, University Medical Center Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J.A.","family":"van Kampen","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC, University Medical Center Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier C.","family":"Manintveld","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thorax Center, Erasmus MC, University Medical Center Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"issue":"2","key":"R1-20231002","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0735-1097(88)90402-0","article-title":"Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings.","volume":"12","author":"Gao","year":"1988","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"R2-20231002","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1056\/NEJM199106203242509","article-title":"Chest pain in heart-transplant recipients.","volume":"324","author":"Schroeder","year":"1991","journal-title":"N Engl J Med"},{"issue":"5 Pt 2","key":"R3-20231002","first-page":"III100","article-title":"Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens.","volume":"80","author":"Gao","year":"1989","journal-title":"Circulation"},{"issue":"3","key":"R4-20231002","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.healun.2011.12.006","article-title":"Prevalence and prognostic value of cardiac allograft vasculopathy 1 year after heart transplantation according to the ISHLT recommended nomenclature.","volume":"31","author":"Prada-Delgado","year":"2012","journal-title":"J Heart Lung Transplant"},{"issue":"8","key":"R5-20231002","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/tri.13141","article-title":"Coronary artery disease in heart transplantation: new concepts for an old disease.","volume":"31","author":"Langstraat","year":"2018","journal-title":"Transpl Int"},{"issue":"10","key":"R6-20231002","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.healun.2017.07.019","article-title":"The registry of the international society for heart and lung transplantation: thirty-fourth adult heart transplantation report-2017; focus theme: allograft ischemic time.","volume":"36","author":"Lund","year":"2017","journal-title":"J Heart Lung Transplant"},{"issue":"6","key":"R7-20231002","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.TP.0000054231.42217.A5","article-title":"Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study.","volume":"75","author":"Potena","year":"2003","journal-title":"Transplantation"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1186\/s12879-015-1321-1","article-title":"Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients.","volume":"15","author":"Johansson","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"8","key":"R9-20231002","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.healun.2015.03.015","article-title":"Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation.","volume":"34","author":"Delgado","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"R10-20231002","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.healun.2009.07.011","article-title":"Does cytomegalovirus serology impact outcome after pediatric heart transplantation?","volume":"28","author":"Mahle","year":"2009","journal-title":"J Heart Lung Transplant"},{"issue":"8","key":"R11-20231002","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/tri.12503","article-title":"Improved long-term survival in Dutch heart transplant patients despite increasing donor age: the Rotterdam experience.","volume":"28","author":"Zijlstra","year":"2015","journal-title":"Transpl Int"},{"issue":"6","key":"R12-20231002","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation.","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"issue":"10","key":"R13-20231002","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1097\/01.TP.0000090163.48433.48","article-title":"Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy.","volume":"76","author":"Fateh-Moghadam","year":"2003","journal-title":"Transplantation"},{"issue":"5","key":"R14-20231002","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.healun.2009.02.009","article-title":"Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.","volume":"28","author":"Potena","year":"2009","journal-title":"J Heart Lung Transplant"},{"issue":"7","key":"R15-20231002","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.healun.2010.05.017","article-title":"International society for heart and lung transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010.","volume":"29","author":"Mehra","year":"2010","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"R16-20231002","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials.","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"2","key":"R17-20231002","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jcv.2011.11.006","article-title":"Real-time PCR versus viral culture on urine as a gold standard in the diagnosis of congenital cytomegalovirus infection.","volume":"53","author":"de Vries","year":"2012","journal-title":"J Clin Virol"},{"issue":"2","key":"R18-20231002","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1128\/JCM.41.2.576-580.2003","article-title":"Diagnosing herpesvirus infections by real-time amplification and rapid culture.","volume":"41","author":"van Doornum","year":"2003","journal-title":"J Clin Microbiol"},{"issue":"4","key":"R19-20231002","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1128\/CMR.00015-13","article-title":"Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation.","volume":"26","author":"Razonable","year":"2013","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"R20-20231002","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/tid.12349","article-title":"Increased risk of breakthrough infection among cytomegalovirus donor-positive\/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.","volume":"17","author":"Stevens","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"R21-20231002","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.healun.2010.04.022","article-title":"Cytomegalovirus disease among donor-positive\/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.","volume":"29","author":"Mitsani","year":"2010","journal-title":"J Heart Lung Transplant"},{"issue":"8","key":"R22-20231002","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.healun.2015.03.002","article-title":"Late antibody-mediated rejection after heart transplantation: mortality, graft function, and fulminant cardiac allograft vasculopathy.","volume":"34","author":"Coutance","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"9","key":"R23-20231002","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.healun.2016.04.007","article-title":"The effect of timing and graft dysfunction on survival and cardiac allograft vasculopathy in antibody-mediated rejection.","volume":"35","author":"Clerkin","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"R24-20231002","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1253\/circj.CJ-15-1037","article-title":"Risk stratification for cardiac allograft vasculopathy in heart transplant recipients - annual intravascular ultrasound evaluation.","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J"},{"issue":"2","key":"R25-20231002","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10554-015-0777-9","article-title":"Increased coronary lipid accumulation in heart transplant recipients with prior high-grade cellular rejection: novel insights from near-infrared spectroscopy.","volume":"32","author":"Zheng","year":"2016","journal-title":"Int J Cardiovasc Imaging"},{"issue":"8","key":"R26-20231002","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.amjcard.2016.01.036","article-title":"Comparison between cardiac allograft vasculopathy and native coronary atherosclerosis by optical coherence tomography.","volume":"117","author":"Shan","year":"2016","journal-title":"Am J Cardiol"},{"issue":"8","key":"R27-20231002","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.healun.2016.03.016","article-title":"Elevated immune monitoring as measured by increased adenosine triphosphate production in activated lymphocytes is associated with accelerated development of cardiac allograft vasculopathy after cardiac transplantation.","volume":"35","author":"Cheng","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"R28-20231002","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.healun.2017.09.011","article-title":"Prevalence of polyreactive innate clones among graft\u2013infiltrating B cells in human cardiac allograft vasculopathy.","volume":"37","author":"Chatterjee","year":"2018","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"R29-20231002","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ajt.13529","article-title":"Late failing heart allografts: pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection.","volume":"16","author":"Loupy","year":"2016","journal-title":"Am J Transplant"},{"issue":"1","key":"R30-20231002","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/ajt.13969","article-title":"Donor-specific antibodies are produced locally in ectopic lymphoid structures in cardiac allografts.","volume":"17","author":"Huibers","year":"2017","journal-title":"Am J Transplant"},{"issue":"5","key":"R31-20231002","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.healun.2014.11.025","article-title":"De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation\u20138-year results.","volume":"34","author":"Guethoff","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"7","key":"R32-20231002","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1097\/TP.0000000000002704","article-title":"Cardiac allograft vasculopathy: the enduring enemy of cardiac transplantation.","volume":"103","author":"Nikolova","year":"2019","journal-title":"Transplantation"},{"issue":"3","key":"R33-20231002","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.transproceed.2013.11.016","article-title":"The effect of statins on cardiac allograft survival.","volume":"46","author":"Luo","year":"2014","journal-title":"Transplant Proc"},{"issue":"12","key":"R34-20231002","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.healun.2011.07.002","article-title":"Safety and efficacy of early aggressive versus cholesterol-driven lipid-lowering strategies in heart transplantation: a pilot, randomized, intravascular ultrasound study.","volume":"30","author":"Potena","year":"2011","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"R35-20231002","doi-asserted-by":"crossref","first-page":"E455","DOI":"10.1111\/j.1399-0012.2011.01459.x","article-title":"The impact of CMV prevention on long-term recipient and graft survival in heart transplant recipients: analysis of the scientific registry of transplant recipients (SRTR) database.","volume":"25","author":"Snydman","year":"2011","journal-title":"Clin Transplant"},{"issue":"10","key":"R36-20231002","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1097\/00007890-200111270-00012","article-title":"Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone.","volume":"72","author":"Valantine","year":"2001","journal-title":"Transplantation"},{"issue":"6","key":"R37-20231002","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1128\/JCM.01362-06","article-title":"Frequent occult infection with cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis.","volume":"45","author":"Potena","year":"2007","journal-title":"J Clin Microbiol"},{"issue":"3","key":"R38-20231002","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/01.tp.0000229039.87735.76","article-title":"Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.","volume":"82","author":"Potena","year":"2006","journal-title":"Transplantation"},{"issue":"Suppl 3","key":"R39-20231002","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/TP.0000000000001096","article-title":"Cytomegalovirus hyper immunoglobulin for CMV prophylaxis in thoracic transplantation.","volume":"100","author":"Rea","year":"2016","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:12:38Z","timestamp":1696223558000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003015","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,21]]}}}